GlassScriptPhysician profile
Jamie C Baines
NPI 1851553762
$5,649.24
in general payments reported to CMS, 2019-2025
38 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $346 · 2021: $983 · 2022: $1,255 · 2023: $1,867 · 2024: $560 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,577.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,060.45 | 2019-2025 | |
| Abbvie INC. | $938.32 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $491.76 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $411.58 | 2021 | |
| Corium, LLC | $233.94 | 2023-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $220.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.95 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $214.69 | 2023-2024 | Shingrix, Bexsero, Rotarix |
| Baxter Healthcare | $207.67 | 2022 | |
| Amgen INC. | $190.40 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $156.41 | 2019-2024 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $137.60 | 2022-2024 | Farxiga, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.08 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Amneal Pharmaceuticals LLC | $101.04 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.80 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $88.54 | 2022-2023 | Seglentis, Livalo |
| Genentech USA, INC. | $86.26 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.99 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $70.67 | 2023-2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $56.22 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $49.36 | 2023 | Quviviq |
| Myriad Women'S Health, INC. | $48.17 | 2023 | Myrisk |
| Grt US Holding, INC. | $36.73 | 2022 | |
| Alk-Abello, INC | $34.64 | 2024 | Ragwitek, Odactra, Grastek |
| Kaleo, INC. | $31.47 | 2023 | Auvi-Q |
| Seqirus USA INC | $30.81 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Novartis Pharmaceuticals Corporation | $29.98 | 2022 | |
| Cranial Technologies, INC | $26.33 | 2020-2022 | |
| Averitas Pharma INC. | $25.98 | 2023 | Qutenza |
| Tris Pharma INC | $25.96 | 2019 | |
| Acclarent, INC | $21.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.06 | 2022 | |
| Nabriva Therapeutics, Plc | $17.48 | 2022 | |
| Acorda Therapeutics, INC | $16.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.39 | 2021 | |
| Allergan, INC. | $14.73 | 2020 | |
| Amarin Pharma, INC. | $13.54 | 2020 | |
| Phadia US INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Baines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.